电休克治疗中神经元损伤与星形胶质细胞反应性的血液生物标志物
本研究纳入99例接受急性电休克治疗的重性抑郁发作患者,在首次治疗前、后及第六次治疗前检测血清神经丝轻链、总tau蛋白和胶质纤维酸性蛋白,并与99名年龄性别匹配的对照比较。基线时患者神经丝轻链和tau蛋白显著高于对照,胶质纤维酸性蛋白仅在首次治疗后短暂升高,未见神经元损伤或长期升高的指标。
要点
- 基线时电休克患者血清神经丝轻链(p<0.001)和tau蛋白(p=0.036)显著高于对照,胶质纤维酸性蛋白无显著差异。
- 首次电休克后胶质纤维酸性蛋白平均升高20.3%(95%CI 14.6%至26.3%,p<0.001),第六次治疗前回落至基线水平。
- 神经丝轻链和总tau蛋白在首次治疗后及第六次治疗前均无显著变化,未见神经元损伤或长期升高的指标。
核心结论
- 电休克治疗可能引起血清胶质纤维酸性蛋白短暂升高,可能反映星形胶质细胞一过性激活。
- 未观察到任何所测生物标志物提示神经元损伤或长期升高的迹象。
研究设计与样本
- 研究纳入99例接受急性电休克治疗的重性抑郁发作患者,并在一般人群中招募99名年龄和性别匹配的对照。
- 在首次电休克治疗前(T0)、首次治疗后30分钟(T1)及第六次治疗前(T2;第五次治疗后48至72小时)采集血液。
- 采用超灵敏单分子阵列法定量血清神经丝轻链、总tau蛋白和胶质纤维酸性蛋白浓度。
- 使用广义最小二乘回归比较基线生物标志物浓度与对照组,并计算从基线至T1及至T2的血清生物标志物浓度变化。
主要发现
- 基线分析显示,电休克组血清神经丝轻链(p<0.001)和tau蛋白(p=0.036)水平显著高于对照组,而胶质纤维酸性蛋白水平无显著差异。
- 与T0相比,血清神经丝轻链浓度在T1(平均变化3.1%,95%CI -0.5%至6.7%,p=0.088)和T2(平均变化-3.2%,95%CI -7.6%至1.5%,p=0.18)均无显著变化。
- 总tau蛋白同样未见变化(平均变化3.7%,95%CI -11.6%至21.7%,p=0.65)。
- 胶质纤维酸性蛋白从T0至T1升高(平均变化20.3%,95%CI 14.6%至26.3%,p<0.001),但从T0至T2无显著变化(平均变化-0.7%,95%CI -5.8%至4.8%,p=0.82)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite electroconvulsive therapy (ECT) being recognized as an effective treatment for major depressive episodes (MDE), its application is subject to controversy due to concerns over cognitive side effects. The pathophysiology of these side effects is not well understood. Here, we examined the effects of ECT on blood-based biomarkers of neuronal injury and astrocytic reactivity. Participants with a major depressive episode (N = 99) underwent acute ECT. Blood was sampled just before (T0) and 30 min after (T1) the first ECT session, as well as just before the sixth session (T2; 48-72 h after the fifth session). Age- and sex-matched controls (N = 99) were recruited from the general population. Serum concentrations of neurofilament light chain (NfL), total tau protein, and glial fibrillary acidic protein (GFAP) were measured with ultrasensitive single-molecule array assays. Utilizing generalized least squares regression, we compared baseline (T0) biomarker concentrations against those of our control group, and calculated the shifts in serum biomarker concentrations from baseline to immediately post-first ECT session (T1), and prior to the sixth session (T2). Baseline analysis revealed that serum levels of NfL (p < 0.001) and tau (p = 0.036) were significantly elevated in ECT recipients compared with controls, whereas GFAP levels showed no significant difference. Relative to T0, serum NfL concentration neither changed at T1 (mean change 3.1%, 95%CI -0.5% to 6.7%, p = 0.088) nor at T2 (mean change -3.2%, 95%CI -7.6% to 1.5%, p = 0.18). Similarly, no change in total tau was observed (mean change 3.7%, 95%CI -11.6% to 21.7%, p = 0.65). GFAP increased from T0 to T1 (mean change 20.3%, 95%CI 14.6 to 26.3%, p < 0.001), but not from T0 to T2 (mean change -0.7%, 95%CI -5.8% to 4.8%, p = 0.82). In conclusion, our findings suggest that ECT induces a temporary increase in serum GFAP, possibly reflecting transient astrocytic activation. Importantly, we observed no indicators of neuronal damage or long-term elevation in any assessed biomarker.
引用
- Sigström R, Göteson A, Joas E, et al. Blood biomarkers of neuronal injury and astrocytic reactivity in electroconvulsive therapy. Mol Psychiatry. 2024. PMID: 39363047. doi:10.1038/s41380-024-02774-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。